Protagonist Therapeutics
PTGX
76 hedge funds and large institutions have $228M invested in Protagonist Therapeutics in 2019 Q3 according to their latest regulatory filings, with 19 funds opening new positions, 29 increasing their positions, 18 reducing their positions, and 9 closing their positions.
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
111% more first-time investments, than exits
New positions opened: 19 | Existing positions closed: 9
61% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 18
15% more funds holding
Funds holding: 66 → 76 (+10)
9% more capital invested
Capital invested by funds: $208M → $228M (+$19M)
1.54% less ownership
Funds ownership: 73.6% → 72.06% (-1.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RI
RTW Investments
New York
|
+$9.61M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$5.74M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$5.45M |
| 4 |
BBA
Baker Bros. Advisors
New York
|
+$2.26M |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$2.22M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BI
BVF Inc
San Francisco,
California
|
-$4.8M |
| 2 |
JP Morgan Chase
New York
|
-$3.49M |
| 3 |
ACP
Acuta Capital Partners
Redwood City,
California
|
-$3.19M |
| 4 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$1.47M |
| 5 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.23M |
PTGX Hedge Fund Activity: Q3 2019 in Review
76 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Protagonist Therapeutics (PTGX) for Q3 2019, worth a combined $228M — up 9.1% from $208M a quarter earlier.
Buyers outnumbered sellers: 19 funds opened new PTGX positions and 9 closed out — a net gain of 10 holders — while 29 added to existing stakes and 18 trimmed.
The largest buyer was RTW Investments, opening a new position worth an estimated $9.61M. The largest seller was BVF Inc, cutting an estimated $4.8M.
- 76 institutional investors held Protagonist Therapeutics (PTGX) as of Q3 2019, up from 66 in Q2 2019.
- Funds reported $228M of Protagonist Therapeutics stock for Q3 2019, up 9.1% quarter-over-quarter.
- 19 funds opened new Protagonist Therapeutics positions in Q3 2019 and 9 closed out, a net change of +10 holders.
- The largest Protagonist Therapeutics buyer in Q3 2019 was RTW Investments, an estimated $9.61M added.
- The largest Protagonist Therapeutics seller in Q3 2019 was BVF Inc, an estimated $4.8M sold.
Based on aggregated 13F filings for Q3 2019.